• The approach to catheterization should be individualized for each patient, with knowledge of the clinical presentation to facilitate the planning of the procedure and the acquisition of the relevant data.
• Determination of valve gradients may require direct measurement of chamber pressures. The use of surrogate measurements (e.g., femoral artery for central aorta; pulmonary capillary wedge for left atrial pressure) may lead to signifi cant errors in the assessment of valve gradients.
• It is important to critically examine the absolute pressure in each chamber, its contour, and the relation between each of the pressures examined.
• Among patients with a discrepancy between the clinical history and resting hemodynamic fi ndings, exercise testing with pressure measurements in the laboratory can be helpful. • Valve morphology is the primary determinant of outcome in patients who undergo percutaneous mitral balloon valvuloplasty.
In the 1960s, cardiac catheterization emerged as the principal diagnostic modality for the evaluation of the patient with valvular heart disease. Two-dimensional echocardiography subsequently allowed visualization of valve morphology and motion as well as the assessment of the ventricular response to the valvular lesions. The advent of Doppler echocardiography in the 1980s provided a noninvasive method for determination of valve gradients, valve areas, and intracardiac pressures. Thus, there has been a shift in the evaluation of patients with valvular heart disease, with the initial diagnostic approach consisting of a comprehensive two-dimensional and Doppler echocardiogram following the history and physical examination. When the clinical and echocardiographic fi ndings are concordant, catheterization is needed only to assess the status of the coronary arteries. Cardiac catheterization, however, still remains essential for many patients with valvular heart disease. Although echocardiography can diagnose the presence and severity of valvular lesions, there are limitations to its accuracy. Thus, the major indication for further assessment with hemodynamic catheterization is when there is a discrepancy between clinical and echocardiographic fi ndings. Absolute intracardiac pressures cannot be assessed by Doppler echocardiography, and cardiac catheterization needs to be performed when this information is necessary. Finally, there has been the evolution of catheter-based therapies for patients with valvular heart disease, which in many cases obviates the need for open-heart surgery.
As the cardiac catheterization laboratory has focused increasingly on acute and chronic coronary syndromes, less attention has been focused on the proper performance and understanding of the hemodynamic assessment of patients with valvular heart disease. The patients with valvular heart disease currently being evaluated in the catheterization laboratory are now those with more complex problems, since patients with straightforward valvular lesions can be assessed primarily with noninvasive methods. Thus, accurate and clinically relevant data from invasive catheterization has become increasingly important for patients with valvular heart disease.
Principles and Techniques
General Approach to the Patient with Valvular Heart Disease in the Catheterization Laboratory
The approach to the hemodynamic assessment of valvular heart disease should be individualized for each patient. The invasive cardiologist performing the study should have full knowledge of what tests has been performed previously, what information is known, and what clinically relevant information is required from the study. A comprehensive differential diagnosis of the patient's problems is needed and facilitates the planning of the procedure. Before proceeding, the vascular access sites and approach to gathering data should be delineated fully.
While all patients should be fasting for the catheterization procedure, intravenous fl uids should be administered to patients who have a long waiting period between their last oral intake and the procedure. This prevents the hemodynamic measurements from being taken during a low-output, low-volume state. Patients can be lightly sedated, but should be awake to simulate the hemodynamic milieu of their outpatient state with close approximation of the heart rate and blood pressure that occurs in their usual daily activities. No parenteral oxygen should be administered prior to the procedure to allow measurements of oxygen saturations.
Accurate measurement of intracardiac pressures with fl uid-fi lled catheters requires the use of large-bore, rigid catheters with minimization of the tubing length between the catheter and pressure transducer. Attention to potential errors of measurement due to damping, catheter whip, entrapment, and other artifacts is always necessary during an invasive hemodynamic study. Fluid-fi lled catheters can reliably measure mean and absolute intracardiac pressures. However, for analysis of pressure waveforms, instantaneous recordings with high-fi delity micromanometer-tip catheters should be utilized (Millar Instruments, Houston, TX). If possible, continuous recording of all hemodynamic pressures should be made to allow retrospective review of these pressures throughout the entire study.
All hemodynamic measurements should be made before any contrast injections, as iodine contrast may affect the hemodynamic milieu. Equilibration periods of at least 10 minutes should be used to allow hemodynamic stabilization whenever there is any change in the hemodynamic state. This equilibration period always should be applied to measurements taken following infusion of a drug or other intervention such as exercise. Spontaneous changes in heart rate and blood pressure should always be noted during the procedure and documented on the record.
Calculations

Cardiac Output Calculation
Indicator dilution (using thermodilution or indocyanine green dye) and the Fick method constitute the main techniques for measurement of cardiac output in the catheterization laboratory. If available, simultaneous echocardiography with measurement of the left ventricular outfl ow tract diameter and Doppler-derived stroke volume also may be used.
The indicator dilution method uses a bolus infusion of an indicator into the circulation with measurement of its concentration over time at some point downstream from the injection. The area under the concentration versus the time curve is inversely proportional to the cardiac output. This method requires the presence of a mixing chamber between the injection and sampling chambers. In most laboratories, this method is performed using cold saline injected into the right atrium and sampling in the pulmonary artery using a thermodilution balloon-tipped catheter. Indocyanine green dye also can be used as the indicator, with injection into the left atrium or pulmonary artery and sampling in the aorta.
The Fick principle utilizes the difference in oxygen content in the arterial and venous system to measure fl ow. In the absence of an intracardiac shunt, the saturation in the pulmonary artery and the saturation in the systemic circulation can be used to determine the systemic cardiac output. Each gram of hemoglobin carries 1.34 mL of oxygen. Thus, the oxygen content is the saturation · hemoglobin · 1.34. The calculation of cardiac output by Fick also requires that either direct measurement of the oxygen consumption or an assumed number for oxygen consumption (derived from body mass and heart rate) be obtained. The formula for cardiac output by Fick is as follows:
where A − V O 2 is the difference in oxygen saturation between the arterial and venous circulation. There are advantages and disadvantages for each of the different methods used. Cardiac output using the indicator dilution method is inaccurate in the presence of low or high heart rates, signifi cant valvular regurgitation, and irregular rhythms. The Fick method overcomes these limitations, but its accuracy requires a steady state and thus it cannot be used for measurement of acute changes (e.g., during pharmacologic interventions). Furthermore, the Fick method requires simultaneous measurement of oxygen consumption or its assumption with one of several methods. Even under ideal conditions, variability in cardiac output may approach 20% when using thermodilution and 10% to 15% when using the Fick method. If possible, both methods should be performed in an individual study to identify outlier results.
Valve Area Determination
The severity of a stenotic valve lesion is measured directly by the gradient across the valve. However, the gradient is proportional not only to the severity of stenosis but also to the fl ow across the valve. It is for this reason that a calculated "valve area" is required for further assessment of severity. The formula for calculation of stenotic valve areas was originally derived by Gorlin and Gorlin 1 in 1951. This equation is based on two fundamental hydraulic principles: (1) Torricelli's law, which states that the area of an orifi ce is inversely proportional to velocity of fl ow for a given amount of total fl ow across that orifi ce; and (2) the pressure gradient across the orifi ce is directly proportional to the velocity of fl ow. The Gorlin equation is as follows:
where ΔP is the mean transvalvular pressure gradient (mm Hg) and C is an empirical constant that encompasses two coeffi cients: a coeffi cient of orifi ce contraction, which corrects for the area of a jet through an orifi ce being smaller than the true area of the orifi ce, and a coeffi cient of velocity, which accounts for the energy loss as pressure energy is converted to kinetic (or velocity) energy. For mitral valve area calculations, C was derived to be 0.85. 2 For all other valve area calculations, C is assumed to be 1.0. Flow refers to absolute forward fl ow across the valve expressed in millimeters per second and is derived from the cardiac output and the duration of forward fl ow, which is the diastolic fi lling period for the mitral valve and the systolic ejection period for the aortic valve ( Fig. 20.1 ). In general, the total error in valve area calculation using the Gorlin equation is 0.2 cm 2 . However, this error increases signifi cantly in patients with bradycardia or tachycardia. Furthermore, the Gorlin equation is inaccurate for patients with signifi cant coexistent regurgitation because the regurgitant fl ow is not factored into the measurement of fl ow.
A simplifi ed version of the Gorlin equation has been derived. 3 In the derivation of this formula, Hakki and coworkers observed that the product of heart rate, forward fl ow, and the Gorlin constants approximated 1 for most calculations. The Hakki equation is as follows:
Valve area cm Cardiac output L/min 2 ( ) = ( )
ΔP
As in the Gorlin equation, the mean pressure gradient is used for calculation of the valve area using the Hakki equation. Because the proportions of diastolic and systolic fl ow vary with heart rate, the major limitation of the Hakki equation occurs in patients with bradycardia or tachycardia. Errors also occur in patients with coexistent regurgitation.
Techniques
Right and Left Heart Catheterization
Right and left heart catheterization is the mainstay of the hemodynamic assessment of the patient with valvular heart disease. Although each patient requires an individualized approach, there is a standard methodology that comprises the basis for these procedures. Proper performance of the right heart catheterization involves screening oximetry for detection of intracardiac shunts, saturation confi rmation of pulmonary capillary wedge readings, cardiac output determination, and calculation of the pulmonary arteriolar resistance. For measurement of absolute pressures, a large bore, single end-hole balloon wedge catheter is preferred for the right heart catheterization. For patients who require measurements of acute changes in pressure and simultaneous assessment of cardiac output, the multiport balloontipped catheter with thermodilution capability may be used. The left heart catheterization should include measurement of ascending aortic pressure, left ventricular pressure, and arterial saturation. These pressures may be obtained with a pigtail or multipurpose catheter. If intraventricular pressure gradients are suspected, an end-hole catheter should be used. The Judkins coronary catheter should not be utilized for obtaining left heart pressures. A standard approach to left and right heart catheterization begins with obtaining arterial and venous access. In most situations, the femoral sites can be utilized. However, in the presence of severe tricuspid regurgitation with large right-sided chambers, the internal jugular approach enhances the performance of the right heart catheterization. Also, the internal jugular approach should be used when an endomyocardial biopsy is required. Once vascular access has been obtained, the right heart catheter is used to acquire oxygen saturations in the inferior and superior vena cavae for calculation of mixed venous oxygen content and to screen for intracardiac shunts. The right atrial pressure is measured with the catheter in the midportion of the right atrium and FIGURE 20.1. Calculation of transvalvular fl ow and gradient. This patient had both aortic and mitral stenosis. The forward fl ow rate is derived from systolic ejection period (SEP) for calculation of aortic stenosis and the diastolic fi lling period (DFP) for calculation of mitral stenosis. The diastolic fi lling period encompasses the entire duration of mitral valve opening, including periods of diastasis. Shaded areas indicate areas for mean gradient across the aortic valve (A) and mitral valve (B). Ao, aortic pressure; C, Gorlin constant; CO, cardiac output; DFP, diastolic fi lling period; LA, left atrial pressure; LV, left ventricular pressure; SEP, systolic ejection period. turned to its lateral wall to avoid prolapse across the tricuspid valve. Ascending aortic pressure is then measured by placement of the left heart catheter, followed by advancement of the catheter into the left ventricle to measure simultaneous left ventricular and right atrial pressures. The right heart catheter is then advanced into the right ventricle to measure simultaneous right ventricular and left ventricular pressures. Finally, the right heart catheter is placed into the pulmonary artery. This sequence of catheter placement and advancement allows prospective examination of the relation between the pressures of the left ventricle and right-sided chambers, which may be particularly helpful in patients who may have concomitant pericardial disease, restrictive cardiomyopathy, or other diastolic dysfunction. With the catheter in the pulmonary artery, simultaneous saturations from the pulmonary artery and left ventricle are obtained for calculation of cardiac output by the Fick method. Finally, the pulmonary artery wedge pressure is obtained with confi rmation of the oxygen saturation. Pulmonary arteriolar resistance should then be calculated from these measurements.
In the presence of elevated pulmonary arteriolar resistance, prognostic information may be obtained using pharmacologic interventions. Several agents have been used for this purpose. In general, selective pulmonary arteriolar dilators (e.g., prostacyclin) are useful in determining the response of the patient with pulmonary hypertension to vasodilator therapy. These selective vasodilators should not be used in patients with elevation of left atrial pressure because of the potential for pulmonary edema. In these instances, agents with capability for dilating both the pulmonary and systemic vascular beds (e.g., nitroprusside) should be utilized. The response of the pulmonary arteriolar resistance to pharmacologic interventions is useful for predicting chronic response to vasodilator therapy, reduction of pulmonary pressure with left-sided interventions, and candidacy for cardiac transplantation.
Transseptal Puncture
The main indications for transseptal puncture are direct measurement of left atrial pressure, assessment of the left ventricle to avoid catheter entrapment from a transaortic approach, access to the left ventricle with an aortic valve prosthesis, and performance of percutaneous mitral balloon valvotomy. The ideal puncture site is the fossa ovalis. The location of the puncture should be assessed by either biplane fl uoroscopy or echocardiography to avoid injury to adjacent structures (aorta, coronary sinus, tricuspid valve) ( Fig. 20.2 ). 4 If fl uoroscopy is used, a catheter in the ascending aorta should be placed to ensure that the puncture is posterior to the aortic root. Both a Mullins sheath as well as a preformed Brockenbrough needle are tools that aid in proper performance of this technique.
After venous access is obtained, a 0.032-inch straight wire via the right femoral vein is used to place an 8-French (F) Mullins sheath and dilator in the superior vena cava. The Brockenbrough needle is inserted into the dilator with the tip just within the end of dilator. The location of the aortic valve is marked with an arterial diagnostic catheter, and biplane fl uoroscopy is used to guide the approach. On frontal plane fl uoroscopy, the puncture site is located at the intersection of a horizontal line (M-line) from the tricuspid annulus to the lateral border of the right atrium and a vertical line that divides the left atrium into anterior and posterior halves ( Fig. 20.2 ). On lateral fl uoroscopy, the puncture site is located two thirds of the distance from the aortic valve to the posterior border of the left atrium. Of note, in patients with vertical hearts, the ideal puncture site may be superior to the horizontal M line. In patients with an enlarged left atrium, the medial left atrial border may protrude beyond the right atrial free wall, thus precluding the use of the M line for landmarks. The atrial septum may lie in a more horizontal plane in patients with a large left atrium.
With the transseptal needle fi xed inside the dilator, the assembly is rotated posteromedially (around 4 o'clock on the direction indicator) and moved inferiorly from the superior vena cava to the atrial septum. The assembly will move rightward (toward the patient's left) as it passes into the right atrium and as it moves over the superior limbus of the fossa ovalis. Slight fl exion of the catheter tip with gentle advancement of the catheter assembly will occur against the limbus when it is located in the fossa ovalis. Advancement of the assembly across the atrial septum is accomplished with gentle pressure and slight protrusion of the Brockenbrough needle beyond the introducer tip. The location of the assembly in the left atrium is confi rmed with pressure transduction, oximetry, or contrast injection. Anticoagulation with heparin is administered once access into the left atrium has been obtained. Following advancement of the sheath into the left atrium, the introducer and needle are removed with counterclockwise rotation of the sheath, resulting in an anterior direction and facilitating access into the left ventricle. The sheath is vigorously aspirated and then fl ushed with heparinized saline. Injury of adjacent structures and cardiac perforation with tamponade are the main complications of transseptal puncture; these occur in less than 3% of patients. 5, 6 Direct Apical Left Ventricular Puncture (Brock Procedure)
The Brock procedure is reserved for patients who require direct measurement of left ventricular pressure, such as those who have both mitral and aortic mechanical valve prostheses that prohibit transvalvular access. The puncture site is at the left ventricular apex, which is located by fl uoroscopy or echocardiography. Following location of the site and scrubbing and draping it, local anesthesia is used to infi ltrate the region at a location superior to a rib. An 18-or 21-gauge needle with a multihole sheath and inner stylet is advanced over the superior rib border and parallel to the long axis of the left ventricle. Premature ventricular beats followed by pulsatile fl ow after removal of the stylet indicate access into the left ventricle. The sheath itself can then be used to measure pressures. Complications of apical puncture include tamponade or pneumothorax in 3%, pleuritic chest discomfort in 10%, vagal-mediated hypotension in 5%, and lower incidences (<1%) of hemothorax, ventricular fi brillation, and coronary artery laceration. 7, 8 
Aortic Stenosis
Overview Due to the aging population, senile degenerative aortic stenosis has emerged as a common etiology of patients presenting with symptomatic severe valve disease requiring intervention. The classic presentation of the triad of dyspnea, angina, and syncope in conjunction with a harsh, latepeaking murmur on auscultation provides the clinician with the suspicion of critical aortic stenosis. Two-dimensional echocardiography can identify the calcifi ed stenotic aortic valve, and Doppler echocardiography reliably estimates the severity of aortic stenosis in the majority of patients.
When the noninvasive assessment demonstrates a high mean aortic valve gradient (>50 mm Hg) that correlates with the physical examination, no further hemodynamic assessment is needed, as severe aortic stenosis is unequivocally present. However, errors may occur in the noninvasive assessment of the severity of the stenosis, mainly from poor alignment of the Doppler signal with the aortic jet, which results in underestimation of the gradient. When there is a discrepancy between the clinical and echocardiographic fi ndings in these patients with aortic stenosis, invasive aortic valve assessment is indicated.
Gradient Determination
The assessment of the severity of aortic stenosis requires accurate measurement of the left ventricular and ascending aortic pressures and of cardiac output. The left ventricular and ascending aortic pressures should be measured simultaneously, either via two arterial accesses or a single arterial access and a transseptal puncture for left ventricular pressure. The mean aortic gradient should be measured from these two simultaneous pressures, using the average of three consecutive beats. In the presence of irregular rhythms, at least eight to 10 sequential beats should be measured. The mean aortic valve gradient alone can be used to help defi ne the severity of aortic valvular stenosis in patients with a normal cardiac output in the absence of signifi cant aortic regurgitation (mild, <25 mm Hg; moderate, 25 to 49 mm Hg; severe, ≥50 mm Hg).
The pullback of a single catheter from the left ventricle to the aorta may sometimes be performed to determine the peak-to-peak systolic gradient. However, this method is subject to error because variation in the beat-to-beat pressure can occur due to respiration changes and variations in the R-R interval. Importantly, the peak-to-peak gradient is not physiologic because it is derived from nonsimultaneous recordings ( Fig. 20.3 ). The peak-to-peak gradient may approximate the true mean aortic valve gradient in some circumstances, particularly at high-pressure gradients (>50 mm Hg). However, the peak-to-peak gradient does not accurately refl ect lower aortic valve gradients, and may be erroneous in patients with low cardiac output or irregular arrhythmia.
In some laboratories, the femoral artery pressure obtained from the sidearm of the sheath is substituted for the ascending aortic pressure. Errors in aortic valve assessment with this method occur because of the time delay for the pressure wave to travel from the ascending aorta to the periphery, and because of the overshoot phenomenon that is characteristic of peripheral artery pressures ( Fig. 20.4 ). Pressure overshoot is due to amplifi cation of the pressure wavefront as it travels from a large channel (i.e., aorta) to smaller conduits without a proportional decrease in fl ow, and is especially prominent in elderly patients with poorly compliant arteries. While various methods have been proposed to adjust for the potential errors from the use of femoral artery pressure, they are prone to inaccuracy and cannot be applied to an individual patient. 9 Although the femoral artery pressure should not be used for determination of an aortic valve gradient, this femoral artery pressure may be examined for the Carabello sign, in which peripheral pressure increases during catheter pullback from the left ventricle to the aorta. 10 This phenomenon is believed to be due to partial obstruction of the aortic valve orifi ce by the catheter, which resolves during its pullback into the aorta. A signifi cant rise in femoral artery pressure (>10 mm Hg) following catheter pullback has been associated specifi cally with aortic valve areas of <0.6 cm 2 .
c h a p t e r 2 0
Aortic Valve Area
The gradient across the aortic valve is dependent not only on the severity of obstruction but also on the fl ow through the valve. Thus, calculation of the aortic valve area provides incremental information to the mean gradient. Based on the Gorlin equation, the aortic valve area is calculated from the following formula:
Valve area cm Heart rate
where CO is the cardiac output in mL/min, SEP is the systolic ejection period in seconds per beat, and heart rate is in beats per minute. The systolic ejection period is the time duration from the aortic valve opening to the dicrotic notch ( Fig. 20.1 ). Normal aortic valve areas range from 3.0 to 4.0 cm 2 . In general, severe aortic stenosis is less than 1.0 cm 2 (Table  20 .1). In patients with a large or small body size, the valve area may be normalized to body surface area (m 2 ). In these circumstances, severe aortic stenosis is commonly defi ned as an indexed valve area of less than 0.5 cm 2 /m 2 . The Hakki equation can be used to calculate aortic valve area in the absence of signifi cant bradycardia, tachycardia, or a low output state. This method uses the mean gradient across the aortic valve, and is usually within 10% of the valve area calculated from the Gorlin equation. 3 In both equations, Single arterial access has been used for measurement of the aortic valve gradient. One method utilizes an 8F doublelumen pigtail catheter that is advanced retrograde into the left ventricle. 11 This catheter contains a side hole located 10 cm proximal to the distal end hole, enabling simultaneous measurement of the left ventricle and aortic pressures. Care must be taken to ensure location of the proximal side hole above the aortic valve during pressure measurement. Damping of the pressure may occur due to the small lumen of the catheter, resulting in erroneous gradient determinations. Another technique utilizes a 0.014-inch pressure wire (RADI Medical Systems, Uppsala, Sweden) that has a highfi delity, wire-mounted pressure sensor in its distal end. 12 The calibrated pressure wire is placed into the left ventricle through a retrograde diagnostic catheter. The catheter is then withdrawn into the ascending aorta with the pressure wire remaining in the ventricle for simultaneous aortic and ventricular pressure measurements. While this method has been examined in a small series of patients, 13 validation of the pressure wire technique against other standard methods of aortic valve gradient assessment has not yet been performed. 
Aortic Valve Resistance
Valvular resistance has been proposed as an adjunct measure for determining the clinical severity of aortic stenosis. 14, 15 Laminar, nonviscous fl ow through a planar orifi ce is a limiting assumption of the Gorlin equation, which theoretically can be overcome by calculation of valvular resistance. The formula for aortic valve resistance is as follows:
Resistance dynes sec cm Mean gradient mmHg Systolic
In patients with normal systolic function, a valve resistance of >250 dynes · sec · cm −5 has been associated with clinically signifi cant aortic valvular stenosis, whereas a value of <200 dynes · sec · cm −5 likely indicates minimal obstruction. However, the calculation of aortic valve resistance has not been shown to provide incremental information to the mean gradient and valve area. 16 
Caveats
Low-Output, Low-Gradient Stenosis
There is a subset of patients who present with left ventricular systolic dysfunction and a low-output, low-gradient state. The valve area will calculate to be in the range of severe aortic stenosis. Some of these patients have severe aortic stenosis and secondary left ventricular dysfunction due to the long-standing severe pressure overload on the left ventricle. However, other patients have a primary depression in left ventricular systolic dysfunction and concomitant mild aortic stenosis. These patients with only mild aortic stenosis have an overestimation of the severity of stenosis due to the fl ow dependency of the Gorlin equation in conjunction with inadequate opening of the aortic valve from decreased inotropic forces. It is essential to determine the true severity of the aortic stenosis, as only patients with severe aortic stenosis will benefi t from surgical intervention. Dobutamine challenge has been used to differentiate the two pathophysiologic processes in these patients with low-output, low-gradient aortic stenosis.
17 Dobutamine (5 to 40 μg/kg/min) is infused to normalize the cardiac output during hemodynamic measurements of aortic valve gradient. Figure 20 .5 illustrates representative hemodynamic tracings from three patients with low-output, low-gradient aortic stenosis who underwent dobutamine infusion. If the cardiac output normalizes and the valve gradient exceeds 40 mm Hg, severe aortic stenosis is present. Alternatively, in those patients with normalization of cardiac output and no increase in mean gradient (less than 30 mm Hg), only mild aortic stenosis is present. Finally, there is a subset of patients who are not able to increase the cardiac output with dobutamine infusion due to the lack of contractile reserve. This lack of contractile reserve portends a very poor prognosis irrespective of therapy. In one study, all patients with a fi nal valve area of <1.2 cm 2 and a mean gradient >30 mm Hg at peak dobutamine infusion were found to have surgically confi rmed, severe calcifi c aortic stenosis. 17 Furthermore, patients who had contractile reserve (>20% increase in stroke volume with dobutamine) had a lower perioperative mortality and a lower incidence of progressive heart failure and late mortality following aortic valve operation. An alternative method of evaluating the patient with low-output, low-gradient aortic stenosis utilizes nitroprusside to augment forward output, which leads to higher calculated valve areas in patients without severe aortic stenosis. 18 This may be potentially useful in patients with systemic hypertension or resting tachycardia, in whom intravenous dobutamine may be contraindicated.
Levels of Outfl ow Obstruction
Not all patients with left ventricular outfl ow tract obstruction have valvular aortic stenosis. The level of obstruction may be subvalvular, valvular, or even supravalvular. Subvalvular obstruction may be fi xed (discrete subaortic stenosis, abnormally high profi le mitral prosthesis) or dynamic (hypertrophic cardiomyopathy). Although the level of obstruction should be diagnosed at echocardiography, these other types of obstruction may be missed when there are suboptimal echocardiographic images or limited Doppler interrogation.
Other types of outfl ow tract obstruction should be suspected whenever there is a high outfl ow tract gradient without a heavily calcifi ed aortic valve on fl uoroscopy. In the catheterization laboratory, the diagnosis of subvalvular obstruction is made by a pullback of the catheter from the left ventricular apex to the left ventricular base to the aorta, preferably with the use of a single end-hole catheter. In patients with subvalvular obstruction, a systolic gradient is present without a change in diastolic pressure when moving the catheter from the left ventricular apex to the left ventricular base. This fi nding may be missed if the pullback is performed too quickly or when a pigtail catheter with multiple side holes is utilized.
Attention to the aortic pressure contour may provide a further clue to the presence of other types of outfl ow tract obstruction. The aortic pressure contour of aortic stenosis is distinctly different from that seen with the dynamic outfl ow tract obstruction of hypertrophic cardiomyopathy (Fig. 20.6 ). In patients with signifi cant valvular aortic stenosis, the rise in aortic pressure is delayed with a late systolic peak, in contrast to the spike-and-dome confi guration of obstructive hypertrophic cardiomyopathy. A fall or failure to augment the pulse pressure on a beat following a premature ventricular contraction (Brockenbrough response) is diagnostic of dynamic outfl ow tract obstruction (Fig. 20.7 ).
Mitral Stenosis
Overview
The primary etiology of mitral stenosis is rheumatic heart disease. As the incidence of rheumatic disease has decreased in industrialized countries, mitral stenosis has become less common. Nonetheless, mitral stenosis is still prevalent in parts of the United States, particularly in areas with immigrant populations.
In contrast to aortic stenosis, the hemodynamic assessment of mitral stenosis can be accurately and reliably assessed with Doppler echocardiography, since the Doppler beam can be directed parallel to the stenotic jet in nearly all patients. 19 The transmitral gradient obtained by Doppler echocardiography should be considered a "gold standard" in the evaluation of these patients. Cardiac catheterization for the hemodynamic severity of mitral stenosis is indicated only when there is a discrepancy between a patient's symptoms and lesion severity by echocardiography. The additive information from the results of the catheterization include the measurement of absolute left ventricular, left atrial, and pulmonary pressures as well as the response of these pressures to exercise. The severity of concomitant mitral regurgitation also may need to be determined by cardiac catheterization. There was an increase in both cardiac output and gradient in response to dobutamine. The valve area remained 0.8 cm 2 . The patient had severe aortic stenosis at operation and was in New York Heart Association (NYHA) class I following surgery. (B) There was an increase in cardiac output but only a mild change in the gradient. This represents mild aortic stenosis. (C) There was no change in cardiac output, a decrease in the valve gradient, and hypotension occurred during the study. Severe aortic stenosis was found at operation, but the patient died of heart failure 2 years later. Transmitral Gradient
Proper assessment of the severity of mitral valve stenosis at catheterization requires simultaneous left ventricular and left atrial pressure recordings to obtain the mean transmitral gradient. The pulmonary capillary wedge pressure from a right heart catheterization has been used for an indirect measurement of the left atrial pressure. The mean pulmonary capillary wedge pressure accurately refl ects mean left atrial pressure in the absence of pulmonary veno-occlusive disease or cor triatriatum. However, there is a signifi cant overestimation of the transmitral gradient (>50% in some cases) when using the pulmonary capillary wedge pressure and left ventricular pressure (Fig. 20.8 ). This overestimation may occur in part because of the time delay (usually 50 to 70 ms) for the (Fig. 20.9) . 19 Phase shifting to align the v-wave peak of the wedge pressure curve to coincide with the relaxation phase of the left ventricular pressure tracing may be performed to help correct for the temporal delay. However, even with proper temporal alignment of the wedge pressure, there is a blunting of the y descent, which results in a 20% to 30% overestimation of the transmitral gradient. Thus if catheterization is required for an accurate assessment of the transmitral gradient, a transseptal approach is necessary to obtain a direct measurement of left atrial pressure.
Mitral Valve Area and Diastolic Half-Time
As with aortic stenosis, the mean transmitral gradient is dependent not only on the severity of the stenosis but also on the fl ow through the mitral valve. Thus, a mitral valve area should be calculated as part of the hemodynamic assessment of a patient with mitral stenosis. Based on the Gorlin equation, the mitral valve area is calculated from the following formula:
Mitral valve area cm heart rate
where DFP is the diastolic fi lling period (seconds per beat). The diastolic fi lling period is measured from the entire period of mitral valve opening to closure. The normal mitral valve has an area of 4.0 to 5.0 cm 2 . Exertional symptoms may occur in patients with mitral valve areas of <2.5 cm 2 . Severe mitral stenosis is usually defi ned as a valve area of ≤1.0 cm 2 , when transmitral gradients >10 mm Hg are present with a normal cardiac output (Table 20. 2). An accurate invasive assessment of valve area requires an accurate measurement of transmitral gradient, which at catheterization is possible only with direct left atrial pressure measurements.
The diastolic half-time is a semiquantitative, adjunctive measure for assessing the severity of mitral stenosis. 20 Its principle is based on the observation that the rate of decay in the transmitral gradient is exponentially and inversely related to the degree of valvular obstruction. 21 Diastolic halftime is calculated as the time in which the peak transmitral gradient declines by 50% (Fig. 20.10 ). Since the rate of pressure gradient fall is not dependent on transmitral fl ow, the diastolic half-time can be used to estimate the severity of stenosis in patients with mitral regurgitation and irregular arrhythmia (i.e., atrial fi brillation). The primary determinants of diastolic half-time are the peak transmitral gradient and the relative compliance between left atrium and left ventricle. Thus, the half-time may be inaccurate when used in patients with severe abnormalities of ventricular compliance, such as restrictive or hypertrophic cardiomyopathy, or after interventions that result in acute changes in net atrioventricular compliance, such as percutaneous or surgical valvotomy. 22, 23 Severe aortic regurgitation also abbreviates the diastolic half-time. Values of diastolic half-time for grading the severity of mitral stenosis are as follows: 100 ms, mild; 200 ms, moderate; and 300 ms, severe.
Exercise Testing
For any given orifi ce area, the transmitral gradient is proportional to the square of the transvalvular fl ow rate. Thus, some patients who have relatively mild hemodynamic abnor-A B C D malities at rest may experience symptoms related to their mitral stenosis with exertion. 24 For patients whose symptoms are out of proportion to the resting hemodynamics, formal exercise testing with hemodynamics may be warranted. Testing may be done invasively with right-and leftheart catheterization or noninvasively with Doppler echocardiography. [25] [26] [27] [28] The advantages of invasive catheterization are the ability to directly measure the pulmonary artery, left atrial or pulmonary capillary wedge, and left ventricular diastolic pressures at rest and during exercise.
The optimal approach for exercise hemodynamics is to utilize exercise that simulates physiologic stress, such as a supine or upright bicycle. Other approaches have utilized arm ergometry or pharmacologic stress, but these techniques provide less relevant clinical information than exercise. Arterial or ventricular pacing (if atrial fi brillation is present) can be used to increase heart rate and decrease the diastolic fi lling period, which is a primary determinant of the gradient in patients with mitral stenosis.
The objective of the exercise hemodynamic study is twofold. The fi rst objective is to measure the transmitral gradient at rest and exercise. A rise in transmitral gradient to that exceeding 20 mm Hg during exercise associated with symptoms may be considered an indication for percutaneous or surgical relief of mitral obstruction. 29 The second objective is to examine the rise in absolute pressures and their relation during exercise. In some patients, the left ventricular diastolic pressure will rise signifi cantly in conjunction with only a mild increase in transmitral gradient, indicating left ventricular diastolic dysfunction as an etiology for symptoms ( Fig. 20.11) . In other patients, there will be a rise in (Top) This patient had marked exercise intolerance but resting hemodynamics were consistent with mild mitral stenosis. With an increase in heart rate to 120 bpm, there was a signifi cant increase in the transmitral gradient (shaded area). (Bottom) This patient also had symptoms of exercise intolerance. With exercise, there was a mild increase in the transmitral gradient (shaded area). However, there were marked increases in the left ventricular (LV) diastolic pressure with relatively rapid fi lling (arrows), as well as in the left atrial (LA), and pulmonary artery (PA) pressure. The increases in LV, LA, and PA pressures were proportional to the increase in systemic hypertension, consistent with exercise-induced diastolic dysfunction. Ao, aortic pressure. pulmonary artery pressure out of proportion to the rise in the left atrial or pulmonary capillary wedge pressure, supporting a pulmonary etiology for the symptoms.
Caveats
The valve area calculation derived by cardiac catheterization may not be accurate in several circumstances. First, the valve area calculation is dependent on accurate measurement of the transmitral gradient. Thus, signifi cant errors will occur when the pulmonary capillary wedge pressure is used, frequently leading to an overestimation of the transmitral gradient and a falsely small valve area. The calculation of mitral valve area using the Gorlin equation also is highly dependent on accurate measurement of transvalvular fl ow (i.e., cardiac output). Since patients with mitral stenosis may have atrial fi brillation and tricuspid regurgitation, cardiac output assessed by the thermodilution method may not be accurate in such patients. Concomitant mitral regurgitation precludes accurate measurement of the mitral valve area due to the increased fl ow across the mitral valve. A large transmitral gradient with a short half-time may be an indicator of severe mitral regurgitation.
An elevation in pulmonary pressures that is out of proportion to the transmitral gradient and mitral valve area should alert the physician to the presence of concomitant disorders such as pulmonary disease, mitral regurgitation, or other causes of elevated left-sided diastolic pressures (Fig.  20.11 ). The pulmonary artery end diastolic pressure should approximate the left atrial pressure. If the pulmonary artery end diastolic pressure exceeds the left atrial pressure by 10 mm Hg, intrinsic pulmonary disease should be suspected. Long-standing severe mitral stenosis may lead to pulmonary arteriolar disease, in which the pulmonary pressure will be elevated out of proportion to the elevation of left atrial pressure.
Valvular Regurgitation
Overview
The workup of the patient with aortic and mitral regurgitation requires an assessment of the etiology and severity of the valve regurgitation as well as the ventricular response to the volume overload. This is especially important in the asymptomatic patient, as early valve operation is now being recommended to prevent the detrimental long-term consequences of the volume overload on left ventricular function. Two-dimensional and Doppler echocardiography have become standard for assessing the etiology of the valve lesion and the status of the left ventricle. However, there are major limitations to the Doppler assessment of the severity of the regurgitation by current methods using only color fl ow imaging.
In the patient with clinically severe mitral regurgitation and defi nitive noninvasive evidence of severe mitral regurgitation (e.g., an unsupported mitral leafl et on echocardiography and a large eccentric jet of mitral regurgitation on color fl ow imaging), no other hemodynamic information is required. However, in the absence of any of these three fi ndings (clinical exam, two-dimensional echo fi ndings compatible with severe regurgitation, color fl ow Doppler fi ndings of severe regurgitation), further invasive evaluation is warranted. This information obtained at cardiac catheterization includes pressure measurements of the hemodynamic consequences of the valve regurgitation, as well as assessment of the severity of valve regurgitation by contrast angiography.
Pressures and Pressure Contours
The severity of regurgitant valvular lesions can be assessed indirectly by examination of pressure contours. In patients with severe mitral regurgitation, the left atrial or pulmonary capillary wedge pressure tracing may have a large v wave due to a rise in left atrial pressure from systolic regurgitation back into the left atrium (Fig. 20.12) . However, the height of the v wave is also inversely related to atrial compliance and directly proportional to cardiac output and systemic vascular resistance. 30, 31 Thus, there may be a large v wave in the absence of severe mitral regurgitation in patients with severe diastolic dysfunction. Severe mitral regurgitation also may not produce a v wave if there is a compliant atrium. Therefore, the fi nding of a large v wave is consistent but not diagnostic of severe mitral regurgitation.
The pulmonary pressure is also an indirect measurement of mitral regurgitation. Although it may be elevated due to a number of other reasons, an indication for intervention on the patient with few or no symptoms and severe mitral regurgitation is the presence of pulmonary hypertension. Thus an accurate measurement of the pulmonary pressure is helpful for decision making regarding the timing of operation in patients with mitral regurgitation.
Patients with chronic severe aortic regurgitation usually have a widened aortic pulse pressure from augmented stroke volume during systole and a large regurgitant volume during diastole resulting in a rapid decline in aortic diastolic pressure ( Fig. 20.13 ). There will be a rapid rise in left ventricular diastolic pressure, especially in patients with a decompensated left ventricle. In patients with acute aortic regurgitation, a widened aortic pulse pressure may not be present, but there will be a rapid elevation of left ventricular diastolic pressure.
In all patients with severe tricuspid regurgitation, the right atrial pressure will be elevated. There usually is a large v wave in the right atrial pressure tracing, which rises early (i.e., cv wave) and, in extreme cases, may resemble the contour of the right ventricle. When there is a high compliance of the right atrium and adjacent vena cava, the cv wave due to tricuspid regurgitation may be blunted (Fig. 20.14) . Early rapid fi lling in the right ventricular pressure tracing (i.e., dip-andplateau) occurs in severe tricuspid regurgitation due to volume overload and a decreased effective operative compliance of the right ventricle. Pericardial restraint occurs if there is severe right ventricular enlargement, resulting in elevation and equalization of diastolic pressures in the left and right ventricular traces, which can simulate the hemodynamic fi ndings of restrictive cardiomyopathy and constrictive pericarditis (Fig. 20.15) . The right atrial-right ventricular gradient during diastole should be examined in these patients to rule out concomitant tricuspid stenosis, ] is preferred to allow two views of the receiving chamber. Contrast volume and injection rates typically are 40 to 50 mL at 12 to 15 mL/sec for mitral or tricuspid regurgitation, and 50 to 60 mL at 20 mL/sec for aortic regurgitation. It is important to use a large-bore catheter to avoid "whip" of the catheter during the injection. In patients with mitral and tricuspid regurgitation, a 6F or larger pigtail or Rodriguez catheter is recommended. A 5F or larger pigtail with a large bore is recommended for aortic root injections. When performing left ventriculography for mitral regurgitation, it is important set up the RAO projection to ensure that the left atrium and descending aorta do not overlap, as this overlap may mask the entry of dye into the left atrium. This setup may require increasing the RAO angle to 40 to 45 degrees. It is critical to position the catheter to avoid ventricular ectopy during the injection. A pigtail catheter should be placed at the base of the heart with the curve of the pigtail away from the septum on the LAO view. Test injections during deep inspiration are used to ensure optimal position of the catheter without ectopy or catheter-induced mitral regurgitation during the contrast injection.
The Sellers criterion for regurgitation severity is the standard for semiquantitation of valve regurgitation (Table 20. 3). 32 The degree of opacifi cation of the receiving chamber by contrast is dependent not only on the severity of regurgitation but also on the amount of contrast injected, rate of injection, ventricular function, and size of the heart chambers. The severity of regurgitation cannot be assessed if there is ventricular ectopy produced during the injection. Although there are many limitations to this angiographic technique, this method has been used as the standard by which surgical decisions have been made for decades, and current outcome data for patients with valve disease is based on this method. Similar angiographic methods are used to grade the severity of aortic regurgitation and tricuspid regurgitation.
Regurgitant Fraction and Regurgitant Volume
Calculation of regurgitant fraction and regurgitant volume provide a more quantitative method for determining the severity of regurgitation. However, this is a method that can be reliably performed only in laboratories that have expertise in this measurement, and thus is not routinely done in contemporary practice. Regurgitant fraction is the proportion of the volume of regurgitation to the total amount of blood ejected from the left ventricle. The total amount of blood In general, valvular regurgitation is graded as mild for regurgitation fraction <20%, moderate for 20 to 40%, moderately severe for >40 to 60%, and severe for >60%. A regurgitant fraction also cannot be used when both signifi cant aortic and mitral regurgitation are present. The major limitation of regurgitant fraction is its reliance on ventriculography for accurate volume assessment. Unless the laboratory has an expertise in reliable reproducible measurement of ventricular volume, this method should not be used.
Prosthetic Valves
Overview
The implantation of a prosthetic valve is a lifesaving procedure for the patient with severe valvular heart disease. Prosthetic valves may eventually malfunction, either with obstruction (from thrombosis or pannus formation) or regurgitation (periprosthetic or through a prosthesis). The noninvasive assessment of prosthetic valve malfunction is more diffi cult than with native valves. Thus, the catheterization laboratory plays a major role in the hemodynamic evaluation of the patients with suspected prosthetic valve malfunction. However, the invasive evaluation of a patient with a prosthetic valve itself can be very challenging as the prosthesis itself may prohibit access to the cardiac chambers. The two-dimensional echocardiographic evaluation of the patient with a suspected prosthetic malfunction is limited by acoustic shadowing that is produced by the prosthesis. This shadowing decreases the ability to visualize disk or poppet motion, and prevents assessment of prosthetic valve regurgitation by color fl ow Doppler imaging. This is particularly pertinent in patients with regurgitant mitral prostheses, in whom imaging of color fl ow jets in the left atrium is severely hampered by the acoustic shadowing of the prosthesis.
As with native mitral valve stenosis, the Doppler transmitral gradient in the patient with a mitral valve prosthesis is reliable and accurate. The transmitral gradient by Doppler is more accurate than that obtained by conventional cardiac catheterization using a pulmonary capillary wedge pressure, due to the inherent problems of the wedge pressure as previously described. However, the Doppler evaluation of an aortic prosthetic valve may not accurately refl ect the true degree of obstruction, due to the phenomenon of pressure recovery. This phenomenon refers to the recovery of kinetic energy of blood into a pressure head following its acceleration through the prosthetic orifi ce, which reduces the net pressure loss across the valve. 33 The high velocities within the prosthetic valve detected by Doppler echocardiography will lead to an overestimation of the true effective gradient. The amount of pressure recovery that occurs is directly related to the ratio of the effective orifi ce area to the aortic area at the level of the prosthesis, as smaller ratios predispose toward the development of fl ow eddies that dissipate the blood fl ow and result in loss of the kinetic energy. The pressure recovery phenomenon is particularly prominent in patients with small bileaflet prosthesis (19 to 21 mm) and with small aortas (diameter <3.0 cm).
Approach to Cardiac Catheterization
In patients with suspected prosthetic valve obstruction, cardiac catheterization accurately determines the true severity of obstruction, as the catheterization gradient is not affected by pressure recovery. However, cardiac catheterization in the patient with suspected prosthetic valve malfunction can be challenging, given the obstruction to access that may be presented by the prosthesis. Catheters should not be placed retrograde across mechanical prostheses. Such placement causes hemodynamic alterations in patients with ball-cage and disk prostheses from catheterinduced regurgitation. In addition, placement of a catheter may result in entrapment of the catheter, particularly if it is placed in the minor orifi ce of the tilting disk prosthesis. Retrograde catheterization should be avoided even with the older tissue prostheses, due to calcifi c deposits on the valve leafl ets, which may become dislodged by the catheter. The pulmonary capillary wedge pressure should not be used to determine the transmitral gradient in patients with mitral valve prosthesis. Thus the hemodynamic assessment of valve prostheses may require alternative procedures, such as a transseptal approach or a Brock procedure. It is particularly important in this assessment to obtain simultaneous proximal and distal pressures as well as an accurate measurement of cardiac output. Both the gradient as well as a calculated effective orifi ce area should be obtained when obstruction is suspected.
Fluoroscopy of the prosthetic valve is a useful adjunct to the assessment of mechanical prosthetic valve dysfunction in the cardiac catheterization laboratory. This should be done on all patients to assess proper seating of the valve prosthesis, and to assess disk or poppet motion. Proper fl uoroscopic evaluation requires alignment of the x-ray beam perpendicular to the valve ring and valve disks to permit measurement of the opening, closing, and travel angles of the leafl ets. Normal values of these angles for each specifi c valve type and size have been published (Table 20 .4). [34] [35] [36] [37] Prosthetic dysfunction is usually defi ned as an opening angle less than two standard deviations of the angles derived from a normal prosthesis.
In patients with suspected prosthetic valve regurgitation, contrast angiography may be necessary. Aortic root angiography in patients with aortic prosthesis and left ventriculography in patients with mitral prosthesis may be a required diagnostic modality. As with native valve regurgitation, the upstream pressures may be of additional value in determining the hemodynamic consequence of the regurgitation.
Balloon Mitral Valvotomy
Overview
The pathophysiologic abnormality in the patient with mitral stenosis is obstruction to infl ow due to fusion of the mitral valve commissures. The treatment of mitral stenosis has been either surgical valvotomy to split the commissures or mitral valve replacement. Percutaneous balloon mitral valvotomy was fi rst introduced in the 1980s as an alternative treatment for patients with isolated mitral stenosis. Because of the signifi cant improvements in its technique and the equipment over the years, percutaneous balloon mitral valvotomy presently is the procedure of choice for selected patients with severe mitral stenosis. 38 
Patient Selection and Indications
The success of balloon mitral valvotomy relies on splitting of the valve commissures without acute disruption of the valve leafl ets on the remaining supporting apparatus. Thus, assessment of the valve morphology is crucial in the proper selection of patients for this technique. Several methods for examining the morphology of the mitral valve have been proposed. [39] [40] [41] The primary goal of these methods is to determine the mechanism of commissural fusion and the pliability of the mitral valve, both of which directly correlate with procedural success rate, acute complication rates, and longterm outcome. It is also important to assess the subvalvular apparatus, as retraction, shortening, and fusion of the chordae and papillary muscles will preclude an adequate result from balloon dilatation.
The Abascal score is a well-accepted semiquantitative system that assesses the suitability of the valve morphology for this procedure. 40 In this scoring system, one to four points are assigned according to the morphologic characteristics of the mitral valve and summated (Table 20 .5). A score of ≤8 is indicative of a pliable, noncalcifi ed valve without signifi cant subvalvular fusion and has been shown to be predictive of procedural success and long-term event free survival. [39] [40] [41] In addition to the Abascal score, it is necessary to also determine the presence or absence of calcifi cation in the commissures, since it is the splitting of these commissures that is the dominant mechanism by which balloon valvotomy leads to relief of mitral stenosis. Calcifi cation of the commissures may result in tearing of the valve leafl ets during balloon infl ation due to the differential stress effects of the infl ated balloon. The presence of commissural calcifi cation is more predictive of adverse events than the Abascal score. 41 The 3-year survival free of death, mitral valve replacement, or repeat percutaneous mitral balloon valvotomy is 86% ± 4% among patients without commissural calcium versus 40% ± 11% for those with such calcium (p < .001) (Fig. 20.16 ). While the Abascal score also is predictive of fi nal mitral valve area and long-term outcomes, patients with high Abascal scores may still have a successful balloon valvotomy if there is no heavy calcifi cation of the valve commissures.
Candidates for balloon mitral valvotomy are those patients with symptoms due to moderate or severe mitral stenosis (mitral valve area <1.5 cm 2 ) and a pliable valve that is considered suitable for the procedure. Asymptomatic patients with moderate or severe mitral stenosis also may be considered is there is favorable valve morphology, especially if there is pulmonary hypertension or new onset of atrial fi brillation. In pregnant patients, balloon mitral valvotomy has been used successfully to treat increasing symptoms of heart failure. 42 In patients with heavily calcifi ed immobile mitral valve leafl ets with signifi cant subvalvular fusion, percutaneous mitral balloon valvotomy is associated with higher complication rates (mainly due to severe mitral regurgitation) and lower acute success rates. There is a poorer long-term outcome due to a high restenosis rate. In these patients the increased risk of this procedure must be weighed against the risks of a mitral valve replacement.
Ineligible patients are those with moderate or severe mitral regurgitation because of the potential for worsening of regurgitation that may occur with valvuloplasty. Patients should all have a transesophageal echocardiogram prior to procedure to rule out a left atrial thrombus. If a left atrial thrombus is present, patients may be reconsidered for mitral balloon valvotomy following anticoagulation with warfarin and resolution of the thrombus. However, a persistent thrombus is a contraindication to percutaneous mitral balloon valvotomy.
Technique
The most common technique for balloon mitral valvotomy employs a transvenous, antegrade approach with a single Inoue balloon system. Retrograde, transarterial approaches have been utilized to obviate the need for a transseptal puncture, but this technique is technically challenging with higher complication rates. 43 A double-balloon technique was initially used in which two balloons are infl ated across the mitral valve. However, as compared to the Inoue balloon, the double-balloon technique is associated with higher complication rates of clinically signifi cant atrial septal defects and left ventricular perforation, due to the movement of the balloons during infl ation.
The majority of centers now use the specially designed Inoue balloon. This hourglass-shaped balloon is made so that increasing infl ation pressures will fi rst infl ate the distal end of the balloon in the left ventricle, followed by the proximal end of the balloon in the left atrium to ensure centering and fi xation of the balloon across the mitral valve. Full infl ation of the balloon infl ates the center of the balloon, which dilates the mitral valve. Comparable reduction in the mitral valve gradient occurs with either the double-or single-balloon (Inoue) method. [44] [45] [46] [47] A major advantage of the single-balloon Inoue system over the double-balloon method is the ability to gradually up-size the balloon, less fl uoroscopy time during positioning of the balloon, and the self-centering nature of the Inoue balloon. 48, 49 The technique of performing a successful procedure requires a transseptal puncture directly through the fossa ovalis. Transseptal punctures superior or inferior to the fossa ovalis may result in diffi culty crossing the mitral valve with the balloon catheter. Once the transseptal puncture is performed, anticoagulation with heparin, and baseline assessments of the mitral valve area, gradient, cardiac output, pulmonary blood pressure, and severity of mitral regurgitation are performed. Selection of Inoue balloon size is determined by the patient's height according to the following formula:
Balloon size (mm) = [height (cm) ÷ 10] + 10 Each Inoue balloon catheter is prepared and examined for accuracy of infl ation size prior to insertion. A heavy-duty spring coil guidewire is placed through the transseptal sheath into the left atrium. The transseptal sheath is exchanged for a 14F long dilator, which is used to dilate the interatrial septum. The Inoue balloon is elongated, passed over the guidewire into the left atrium, and then shortened. The spring coil guidewire is exchanged for a J-tipped stylet, which is used to guide the balloon through the mitral orifi ce with care to avoid entanglement of the device and the subvalvular apparatus.
Following removal of the stylet, the distal part of the balloon is infl ated in the left ventricle and pulled back to appose the mitral valve. Sequential infl ation of the proximal compartment and midsection of the balloon follows, facilitating commissural splitting. During the procedure, repeat assessment of the transmitral gradient, severity of mitral regurgitation, and pulmonary pressures with echocardiography or invasive monitoring is performed. Repeated or subsequent dilatation with larger infl ation sizes with the Inoue balloon can be performed in a stepwise fashion in 1-to 2-mm increments until the desired mitral valve area is achieved. After successful dilatation, the balloon is elongated in the left atrium to prevent an atrial septal defect during withdrawal of the balloon back into the right atrium. Following removal of the balloon catheter, an oxygen saturation run is performed to exclude signifi cant left-to-right shunting, and residual mitral regurgitation is assessed by either echocardiography or left ventriculography.
Outcome
Valve morphology is the predominant determinant of outcome and complications after balloon valvotomy. Other factors that are associated with the success rate include age, functional class, ventricular diastolic pressure, severity of stenosis, and cardiac output. 50 In general, there is a doubling of the mitral valve area (usually 1.0 cm 2 to 2.0 cm 2 ) and a 50% to 60% reduction in the transmitral gradient (Fig. 20.17) . Procedure success has been defi ned as a fi nal mitral valve area >1.5 cm 2 and decrease in left atrial pressure to <18 mm Hg in the absence of complications, and it occurs in 70% to 95% of patients, depending on the underlying valve morphology. 51 Complications include acute severe mitral regurgitation in 2% to 10%, large residual atrial septal defect (Qp/Qs > 1.5) in 12% with the double-balloon technique and <5% with the single-balloon system, ventricular perforation in 0.5% to 4%, systemic embolization in 0.5% to 3.0%, myocardial infarction in 0.3% to 0.5%, and mortality in <2%. Given the complexity of the procedure, acute outcomes also have been directly correlated with operator experience. 48, 52, 53 Overall, in patients with favorable morphology, the success rate in experienced hands is greater than 90% with a complication rate of less than 3%.
Event-free survival (freedom from death, repeat valvotomy, or mitral valve replacement) over 3 to 7 years is 50% to 70% overall, but exceeds 90% in those with favorable valve morphology. Randomized, albeit small, investigations have demonstrated comparable clinical outcomes of balloon mitral valvotomy and surgical mitral commissurotomy for selected patients with mitral stenosis. [54] [55] [56] [57] [58] These investigations enrolled primarily young patients (mean age <30 years) with favorable valve morphology) and are summarized in Table  20 .6.
Balloon Aortic Valvotomy
Overview Percutaneous balloon aortic valvotomy was introduced by Lababidi et al. 59 in 1984 and has become the treatment of choice for noncalcifi ed congenital aortic stenosis in children and young adults. In the mid-1980s, Cribier et al. generated great enthusiasm when they successfully performed this procedure in three elderly patients with critical aortic stenosis due to calcifi c degenerative disease. Although there was an acute improvement in hemodynamics and symptom relief in these critically ill patients, subsequent follow-up studies have shown a high restenosis rate and no improvement in survival in these critically ill elderly patients. Thus percutaneous aortic balloon valvotomy in adults now has limited indications and is rarely performed. The following discussion focuses on aortic balloon valvotomy in the older adult.
Patient Selection
Patients with stenosis due to congenital abnormalities of the aortic valve and no signifi cant calcifi cation may have significant relief of obstruction due to splitting of the commissures. [60] [61] [62] However, in patients with senile degenerative aortic 
Technique
The retrograde aortic approach from femoral artery access is most commonly used for balloon aortic valvotomy. Initial measurements are made with one catheter in the left ventricle and the other in the ascending aorta. Following baseline hemodynamic assessment, the left ventricular catheter is exchanged for a 0.038-inch heavy-duty, exchange length (300 cm) guidewire with a "pigtail" curve made at the end of the wire. The prepared, defl ated balloon catheter is then advanced over this guidewire to straddle the aortic valve using the proximal and distal balloon markers. In general, a balloon diameter less than 120% of the annulus size measured on echocardiography is utilized. 63 Most operators start with a 20-mm balloon, but smaller sizes (15 or 18 mm) may be used for patients with smaller body surface area (<1.8 m 2 ). The balloon is infl ated slowly with pressure on the catheter to maintain stable positioning across the aortic valve, followed by rapid infl ation with the appropriate necessary force to reach its maximum diameter. Infl ation is usually less than 10 seconds, using the disappearance of a "waist" on the balloon as a sign that the valve has been adequately dilated. Transient myocardial ischemia, as measured by coronary sinus fl ow and metabolites, occurs during balloon infl ation that resolves immediately with defl ation. 64 Both the myocardial ischemia and the increased afterload imposed by balloon infl ation lead to depression of ventricular function. Systolic blood pressure usually decreases modestly, but can be precipitous in patients with left ventricular dysfunction. In the event that the desired aortic valve area has not been achieved, infl ations can be repeated following a period of stability with larger balloon (23 mm), or, in some instances, double balloons (i.e., two 15-or 18-mm balloons). The double-balloon approach allows venting during infl ation as an attempt to improve patient tolerance. [65] [66] [67] Outcome Several registries have documented the acute hemodynamic benefi ts, complications, and long-term outcomes with balloon aortic valvotomy. The Mansfi eld balloon aortic valve registry reported on 492 patients who underwent the procedure at 27 institutions from 1986 to 1987 in the United States and Europe. 68 The National Heart, Lung, and Blood Institute (NHLBI) Balloon Valvotomy Registry examined the outcomes of 674 patients from 24 institutions in the United States from 1987 to 1989. 69 Overall, these investigations observed an increase in the aortic valve area from 0.5 cm 2 to 0.8 cm 2 , a decrease in the gradient from 60 mm Hg to 30 mm Hg, and little increase in cardiac output.
For patients with degenerative aortic stenosis, complications are a major limitation of balloon aortic valvotomy. These occur in approximately 20% of patients, including stroke in 1.4% to 5.5%, emergency aortic valve replacement in 1.2%, ventricular perforation in 1.4% to 3.6%, local vascular injury in 4.1% to 10.0%, and procedural death in 1.8% to 7.5%. Procedural complications are a strong predictor of in-hospital mortality, occurring most commonly in patients with coronary atherosclerosis, severe functional class, and those who are female. Other important variables associated with in-hospital mortality are left ventricular dysfunction, the severity of aortic stenosis at baseline, and the fi nal valve area. 70 Restenosis of the aortic valve, defi ned as 50% reduction in the acute gain in valve area, occurs in 50 to 65% of these patients at 6 months and reaches nearly 100% at 1 year. 71 There also is a continued high rate of late mortality that is not different from untreated patients, likely due to the severe comorbidities that are present in these highly selected patients. Thus, balloon aortic valvotomy remains a palliative measure rather than an alternative to aortic valve replacement in patients with calcifi c aortic stenosis.
Percutaneous Valve Replacement and Repair
Surgical operation remains the standard approach for valve replacement. Percutaneous valve replacement was fi rst attempted several decades ago, but signifi cant technical hurdles hindered its progress. 72, 73 Nonetheless, in 1992, Andersen and coworkers 74 demonstrated the feasibility of the percutaneous approach by attaching a porcine bioprosthesis to a wire-mounted stent, and successfully implanting the device in various aortic positions. Subsequently, Bonhoeffer and coworkers 75, 76 tested a bovine valve mounted on an expandable stent in animals, and then successfully implanted the device into the pulmonary position in a 12-year-old boy.
In the fi rst reported series in humans, Cribier and coworkers 77 performed percutaneous aortic valve implantation with a 23-mm prosthesis (Cribier-Edwards) in six nonsurgical patients (mean age, 75 years) with end-stage calcifi c aortic stenosis. This prosthesis consists of three bovine pericardial leafl ets mounted on a 15-mm balloon-expandable stainless steel stent (Edwards Lifesciences, Irvine California) delivered via an antegrade approach (Fig. 20.18 ). Successful delivery occurred in fi ve patients with an increase in the effective aortic valve area from 0.5 ± 0.1 cm 2 to 1.70 ± 0.1 cm 2 , a decrease in the gradient from 38 ± 11 mm Hg to 7 ± 3 mm Hg, and an increase in left ventricular ejection fraction from 24% ± 10% to 41% ± 12% at follow-up. Complications included one death due to early migration and severe paravalvular regurgitation in two, but coronary artery patency was preserved in all patients. Other percutaneous aortic valve prostheses include the CoreValve self-expanding prosthesis, which has been implanted in two patients in Europe. Technological devel opment of suitable prostheses is ongoing, with targeting of the major obstacles to successful percutaneous treatment of aortic stenosis. These challenges include (1) accurate placement within the native valve without obstruction of the native coronary arteries; (2) minimizing the risk of embolization of the prosthesis and native valve debris; (3) retention of the prosthetic position without paravalvular regurgitation; and (4) long-term durability.
While balloon valvotomy has become the preferred therapy for selected patients with mitral stenosis, ongoing studies are evaluating percutaneous techniques for mitral valve repair for patients with mitral regurgitation. There have been two main approaches, both of which emulate surgical techniques. The fi rst method employs one or two metallic clips (Evalve Inc., Redwood City, CA) through an antegrade approach. The clips attach the free edges of the midportions of the anterior and posterior mitral valve leafl ets to each other, creating a double-orifi ce valve and reducing mitral regurgitation similar to the surgical Alfi eri repair. 78, 79 In a report of the multicenter Endovascular Valve Edge-to-Edge Repair Study (EVEREST) Phase 1 study, Feldman and coworkers 80 successfully deployed the Evalve clip in 17 symptomatic patients with grade ≥3+ mitral regurgitation. There was a signifi cant reduction in mitral regurgitation with 13 of the patients having residual regurgitation of grade 2+ or less.
The second method emulates surgical mitral annuloplasty by implanting devices in the coronary sinus, whose course roughly parallels the plane of posterior mitral annulus. These devices, when deployed, foreshorten the coronary sinus and thereby plicate or straighten the posterior annulus, leading to a reduction in the mitral annular diameter and regurgitation (Figs. 20.19 and 20.20) . There have been several animal studies demonstrating the potential effi cacy of this approach. [81] [82] [83] The main challenges to this technique will be reliance on the coronary sinus, which can be mobile and is subject to thrombosis, erosions, and other complications as has been demonstrated in studies of patients who undergo biventricular placing; and the proximity of the coronary sinus to the left circumfl ex artery, which may be injured during device deployment. For either percutaneous approach to mitral valve repair, effi cacy as a stand-alone intervention also will need to be compared to open surgery, which is frequently supplemented with other adjunctive measures (e.g., leafl et resection, chordal surgery).
These new technologic advances are potentially a less invasive therapeutic approach to the patient with valvular heart disease. There has been great enthusiasm generated for this concept of catheter-based therapy for these patients. However, the ultimate role of this technology will need to be determined by trials demonstrating the short-and longterm results of these procedures.
